Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$12.76 +7.4%	$10.44	$5.42 ▼ $22.49	$140.49M	1.59	268,207 shs	489,991 shs
ATE Antibe Therapeutics	C$0.30	C$0.51	C$0.15 ▼ C$1.23	C$15.54M	0.12	135,475 shs	N/A
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
ONC Oncolytics Biotech	C$1.47 +2.8%	C$1.44	C$1.20 ▼ C$4.49	C$110.87M	1.49	77,454 shs	29,418 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+7.18%	+40.68%	+7.23%	+40.07%	-13.61%
ATE Antibe Therapeutics	0.00%	0.00%	-31.40%	-67.58%	-45.37%
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
ONC Oncolytics Biotech	+2.80%	+2.08%	+5.00%	-13.53%	-5.16%

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.6189 of 5 stars	3.4	1.0	0.0	0.0	2.8	1.7	0.6
ATE Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	0.5985 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	117.48% Upside
ATE Antibe Therapeutics	2.00	Hold	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	3.00	Buy	C$6.00	308.16% Upside

Current Analyst Ratings

Latest FRX, ATE, ANVS, REDX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/4/2024	ATE Antibe Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A
ATE Antibe Therapeutics	C$9.71M	1.60	C$0.48 per share	0.61	C$0.49 per share	0.60
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
ONC Oncolytics Biotech	N/A	N/A	C$0.35 per share	4.22	C$0.37 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)
ATE Antibe Therapeutics	-C$18.24M	-C$0.35	N/A	∞	N/A	N/A	-52.72%	-19.13%	7/4/2024 (Estimated)
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)

Latest FRX, ATE, ANVS, REDX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/29/2024	Q4 2023	ANVS Annovis Bio	N/A	-$1.09	-$1.09	$0.15	N/A	N/A
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A
2/14/2024	Q3 2024	ATE Antibe Therapeutics	-C$0.12	-C$0.08	+C$0.04	-C$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ATE Antibe Therapeutics	C$0.05	16.95%	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	2.39	2.39
ATE Antibe Therapeutics	0.29	10.06	9.58
FRX Forest Road Acquisition	N/A	0.37	0.37
ONC Oncolytics Biotech	1.54	9.01	8.86

Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
ATE Antibe Therapeutics	N/A
FRX Forest Road Acquisition	N/A
ONC Oncolytics Biotech	6.98%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	38.30%
ATE Antibe Therapeutics	7.94%
FRX Forest Road Acquisition	N/A
ONC Oncolytics Biotech	6.24%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	6	11.01 million	6.79 million	Optionable
ATE Antibe Therapeutics	11	52.67 million	N/A	Not Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable

FRX, ATE, ANVS, REDX, and ONC Headlines

Source	Headline
	Krystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 virus pharmaceutical-technology.com - April 23 at 9:08 AM
	Outrun Therapeutics announces launch with $10m seed funding pharmaceutical-technology.com - April 18 at 7:38 AM
	Biotech expansion for Japanese firm in Holly Springs driven by talent pool, universities carolinapublicpress.org - April 17 at 10:38 AM
	Stocks in play: Oncolytics Biotech® Inc. ca.finance.yahoo.com - April 11 at 3:56 PM
	Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA finance.yahoo.com - April 11 at 8:38 AM
	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 markets.businessinsider.com - April 10 at 6:01 PM
	Oncolytics Biotech is undervalued, Raymond James says cantechletter.com - April 5 at 3:37 PM
	Oncolytics Biotech (TSE:ONC) Trading Up 10.7% marketbeat.com - April 4 at 10:46 AM
	Closing Bell: Oncolytics Bio down on Friday (ONC) theglobeandmail.com - March 16 at 10:14 AM
	Futures Retreat Sharply msn.com - March 11 at 4:05 PM
	Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN finanznachrichten.de - March 6 at 4:39 PM
	Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning finanznachrichten.de - March 6 at 4:39 PM
	A Preview Of Oncolytics Biotech's Earnings benzinga.com - March 6 at 4:39 PM
	Oncolytics Biotech Inc ONC morningstar.com - March 2 at 6:22 PM
	Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline markets.businessinsider.com - February 15 at 9:24 AM
	Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments finance.yahoo.com - February 15 at 9:24 AM
	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies theglobeandmail.com - February 14 at 2:36 PM
	USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024 finanznachrichten.de - February 7 at 11:03 AM
	KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses finance.yahoo.com - January 31 at 8:47 PM
	Oncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictions benzinga.com - January 6 at 3:30 PM
	JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON) markets.businessinsider.com - December 14 at 8:26 AM
	Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS finanznachrichten.de - December 7 at 8:30 AM
	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep finance.yahoo.com - November 9 at 7:48 AM
	Oncolytics Biotech's Earnings Outlook benzinga.com - November 3 at 6:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Lockheed Martin Stock Aims for a Fresh All-Time High
April 23, 2024 9:59 AM
View Lockheed Martin Stock Aims for a Fresh All-Time High
High-Yield Texas Instruments Could Hit New Highs Soon
April 24, 2024 11:27 AM
View High-Yield Texas Instruments Could Hit New Highs Soon
3 Cheap Stocks That Shouldn’t Be Cheap for Long
March 26, 2024 9:49 AM
View 3 Cheap Stocks That Shouldn’t Be Cheap for Long
3 High Dividend Stocks to Replace Lower Savings Yields Ahead
April 9, 2024 9:15 AM
View 3 High Dividend Stocks to Replace Lower Savings Yields Ahead

All Headlines

Company Descriptions

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Antibe Therapeutics

TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Forest Road Acquisition

NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial